Torrent Pharmaceuticals is implementing a voluntary recall for select batches of Semalix injection disposable pens as a precautionary measure. This action follows a product recall notification issued by the manufacturer, Dr. Reddy's Laboratories Ltd., for a technical evaluation. The company emphasized that patient safety is of paramount importance and stated there is no risk to patients already on this treatment due to the recall.

The recall specifically targets Semalix Injection pens in 2 mg and 4 mg dosages that were manufactured by Dr. Reddy's Laboratories Ltd. Torrent Pharmaceuticals clarified that all other Stock Keeping Units (SKUs) of Semaglutide sold by the company remain completely unaffected. This includes oral formulations and other variants produced by different manufacturers.

Affected and Unaffected Products

The company provided a detailed breakdown of the product lines to clarify which items are subject to the recall and which remain available for use. The distinction is based on the specific product type and the manufacturing partner.

Patients or family members currently using any of the listed products have been advised to reach out to pv@torrentpharma.com for further clarification. The company confirmed that the recall is limited to the specific batches mentioned and does not extend to the broader product portfolio.

Torrent Pharmaceuticals Limited has announced that its amalgamation with J B Chemicals & Pharmaceuticals Limited became effective on July 8, 2026. The merger, sanctioned by the National Company Law Tribunal (NCLT), Ahmedabad Bench, on July 6, 2026, was finalized following the filing of the certified tribunal order with the Registrar of Companies. Consequently, J B Chemicals stands amalgamated into and with Torrent Pharmaceuticals and dissolved without being wound up, with the appointed date set as January 21, 2026.

The Scheme of Amalgamation outlines a share exchange ratio of 51 fully paid-up equity shares of Torrent Pharmaceuticals (face value ₹5 each) for every 100 fully paid-up equity shares of J B Chemicals (face value ₹1 each). Torrent Pharmaceuticals Limited acts as the Transferee Company, while J B Chemicals & Pharmaceuticals Limited is the Transferor Company.

Pursuant to the effectiveness of the Scheme, the capital clause of the Memorandum of Association of Torrent Pharmaceuticals has been amended. The authorized capital of the company is now ₹2,55,30,00,000 divided into 46,06,00,000 Equity Shares of ₹5 each and 25,00,000 Preference Shares of ₹100 each.

The disclosure was submitted to BSE Limited and National Stock Exchange of India Ltd in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Chintan M. Trivedi, Company Secretary of Torrent Pharmaceuticals Limited, signed the regulatory filing confirming the effective date and capital structure details.